Search

A visionary program investigates how the body’s ecosystem affects cancer.

… Friday, April 1, 2022 Dear MSK Community,   We are poised at a pivotal moment in cancer research.   For the past few decades, researchers have focused on identifying gene mutations associated with cancer and have developed highly effective drugs to target them. This revolutionary approach, called precision

Temozolomide chemotherapy reduced seizures in 90 percent of patients with World Health Organization (WHO) grade 2 oligodendroglioma and tumor-related epilepsy.

… Friday, June 28, 2019 Temozolomide chemotherapy reduced seizures in 90 percent of patients with World Health Organization (WHO) grade 2 oligodendroglioma and tumor-related epilepsy, according to the results of a recent retrospective study of 39 patients treated at Memorial Sloan Kettering Cancer Center

MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.

… Friday, September 6, 2024 When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS signaling pathways work together to spur the spread of cancer in lung adenocarcinoma

Several Memorial Sloan Kettering Cancer Center (MSK) physician-scientists have been recognized by the American Society of Clinical Oncology (ASCO).

… Thursday, May 30, 2024 Several Memorial Sloan Kettering Cancer Center (MSK) physician-scientists have been recognized by the American Society of Clinical Oncology (ASCO). Every year, ASCO recognizes individuals who have made significant contributions to ASCO, the practice of clinical oncology, people

Chemotherapy is a common treatment for acute myeloid leukemia, but patients often stop responding. Until now, not much was known about why.

… Friday, December 2, 2016 Summary Acute myeloid leukemia is usually treated with chemotherapy , but patients often stop responding to these drugs and develop resistance to them. Now MSK investigators are learning why that is the case. Highlights Acute myeloid leukemia is the most common acute leukemia

Even as a child, physician-scientist Veronica Rotemberg always knew that her future self would be wearing a lab coat. Learn more about her journey and research.

… Monday, April 29, 2024 Veronica Rotemberg, MD, PhD , Director of Dermatology Informatics Program at Memorial Sloan Kettering Cancer Center (MSK), and leader of her own lab at Memorial Hospital, is passionate about her patients, technology, and the future. She has been a member of the MSK faculty for

For many patients, time is of the essence. At MSK, patients have access to potentially lifesaving therapies long before they are available at community hospitals. Learn how MSK’s Cancer Health Equity Research Program (CHERP) partners with a network of public hospitals in New York City to recruit underserved patients for clinical trials at MSK and give them access to world-class care.

… Tuesday, December 6, 2022 Berta Pesantez knew the outlook wasn’t good. She had stage 4 cancer of the bile duct , and the chemotherapy she was receiving at her local hospital wasn’t working. Out of options, the doctor transferred Berta to the New York’s Queens Cancer Center (QCC), in Jamaica. Berta’s

Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes may not require prophylactic central compartment neck dissection, enhancing quality of life.

… Monday, August 17, 2020 Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes (cN1b disease) may not require prophylactic central compartment neck dissection (PCND), according to our retrospective study published recently in the Annals of Surgical Oncology .  (1

A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases.

… Friday, April 6, 2012 Summary A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases. Some cancer treatments — including bone marrow transplantation , chemotherapy, and radiation — can temporarily

A new laboratory study provides evidence about how advanced age can be protective against cancer — with implications for treating patients in different age groups.

… Wednesday, December 4, 2024 When it comes to cancer, aging is a double-edged sword, researchers are increasingly learning. Age is considered the most important risk factor for cancer . That’s because genetic mutations build up in cells over years and decades, and ultimately drive the development of cancer